Coloplast A/S (0QBO.IL)
| Previous Close | 860.80 |
| Open | 811.20 |
| Bid | 821.40 x 0 |
| Ask | 855.80 x 0 |
| Day's Range | 805.60 - 839.20 |
| 52 Week Range | 689.60 - 981.80 |
| Volume | |
| Avg. Volume | 91,420 |
| Market Cap | 192.467B |
| Beta (5Y Monthly) | 0.26 |
| PE Ratio (TTM) | 37.00 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 20.00 (2.76%) |
| Ex-Dividend Date | May 15, 2023 |
| 1y Target Est | N/A |
- GlobeNewswire
Coloplast strengthens ostomy care portfolio with three significant product launches
Heylo Heylo is the world's first digital leakage notification system. SenSuraMio_Black SenSura Mio in black developed to provide more product choice for people living with a stoma. The company has received reimbursement approval in the UK for Heylo™, the world’s first digital leakage notification system, and expands its SenSura® Mio ostomy range with two new products. As part of our 2025 strategy, Strive25, we set an ambition to significantly raise the standard of care for our users and bring ne
- GlobeNewswire
Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24
H1 2023/24Interim financial results, H1 2023/241 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%.Continued go
- GlobeNewswire
Coloplast A/S - Allocation of Share Options
Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address: https://investor
